08 August 2022: Clinical Research
Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
Beatriz Barranco-Fragoso 12ABC , Shreya C. Pal 34CDEFG , Luis E. Díaz-Orozco 34ABCDEF , Rita Dorantes-Heredia 5BCD , Xingshun Qi 6F , Nahum Méndez-Sánchez 34ACDEF*DOI: 10.12659/MSM.937528
Med Sci Monit 2022; 28:e937528
Table 5 Sub-analysis of focal and diffuse expression of hepatic dendritic cells (CD11c+) in MAFLD according to patients’ BMI and histologic stage of disease. Based on the data that the table presents, we can see how the totality of patients who present CD11c+ cell expression or any degree of liver damage also present with focal expression of these cells.
| Patients with MAFLD (n=35) | N (%) | Focal expression of hDCs (CD11c+)30 (85.71%)N (%) | Diffuse expression of hDCs (CD11c+)5 (14.29%)N (%) |
|---|---|---|---|
| Men | 18 (51.43) | 16 (88.89) | 2 (11.11) |
| Women | 17 (48.57) | 14 (82.35) | 3 (17.65) |
| Non-obese | 19 (54.29) | 14 (73.68) | 5 (26.32) |
| Obese grade I–II | 14 (40.00) | 14 (100.00) | 0 (0.00) |
| Morbidly obese | 2 (5.71) | 2 (100.00) | 0 (0.00) |
| Simple steatosis | 5 (14.28) | 4 (80.00) | 1 (20.00) |
| Inflammation | 27 (77.14) | 23 (85.19) | 4 (14.81) |
| Ballooning degeneration | 13 (37.14) | 11 (84.62) | 2 (15.38) |
| Fibrosis | 24 (68.57) | 21 (87.5) | 3 (12.50) |
| BMI – body mass index; hDCs – hepatic dendritic cells; MAFLD – metabolic (dysfunction)-associated fatty liver disease. | |||